Drugs / LEAC-102
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02826837 | Sep 2022 → Feb 2024 | colorectal cancer | Taiwan Leader Biotech Corp. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEAC-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02826837 ↗ |
| Route | Oral | “Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral)” NCT02826837 ↗ |